Thursday, August 29, 2019 11:08:09 AM
It looks like Diwan is setting himself up for a rinse-and-repeat once NNVC closes its doors. I don't blame him, considering how easily he made tens of millions of dollars in the NNVC scam:
http://www.allexcel.com/
"Since 1992, AllExcel, Inc. has been an early pioneer in developing technology in the field of what are now called "nanomedicines". AllExcel has developed as yet unmatched industry leading capabilities in our platform technology that we call "TheraCour®".
TheraCour is a micelle forming, self-assembling, polymeric material that has the unique and highly sought-after capabilities:
> TheraCour can take drugs to specific cancer cells, bacterial cells or virus particles while sparing normal human cells, based on a zip-code-like address based targeting.
> TheraCour enables tailoring of the pharmaceutical lifetime of a drug, as per the requirement of the specific disease and the intervention. It is possible to achieve short term lifetime of a few hours, a medium lifetime of a couple of days, and even weeks. This enables excellent patient compliance.
> TheraCour enables tailoring for optimal drug delivery by any route, be it injectable, transdermal, topical ocular, or even oral. This minimizes the formulation stage in drug development. In contrast, liposomal drugs may require years of formulation optimization.
> TheraCour-based drug candidates have been found to be inherently safe in a multitude of studies against a wide variety of diseases.
> TheraCour-based drug candidates have demonstrated very high effectiveness in a number of animal models of different diseases.
> TheraCour enables encapsulation of therapeutic cells so that they can be manufactured, protected in the TheraCour gel, and implanted into a patient while minimizing cell death from host effects, to cure degenerative diseases such as Diabetes, Liver Disease, Cardiac Muscle, Neurodegenration, Parkinson's Disease and more."
http://www.allexcel.com/
"Since 1992, AllExcel, Inc. has been an early pioneer in developing technology in the field of what are now called "nanomedicines". AllExcel has developed as yet unmatched industry leading capabilities in our platform technology that we call "TheraCour®".
TheraCour is a micelle forming, self-assembling, polymeric material that has the unique and highly sought-after capabilities:
> TheraCour can take drugs to specific cancer cells, bacterial cells or virus particles while sparing normal human cells, based on a zip-code-like address based targeting.
> TheraCour enables tailoring of the pharmaceutical lifetime of a drug, as per the requirement of the specific disease and the intervention. It is possible to achieve short term lifetime of a few hours, a medium lifetime of a couple of days, and even weeks. This enables excellent patient compliance.
> TheraCour enables tailoring for optimal drug delivery by any route, be it injectable, transdermal, topical ocular, or even oral. This minimizes the formulation stage in drug development. In contrast, liposomal drugs may require years of formulation optimization.
> TheraCour-based drug candidates have been found to be inherently safe in a multitude of studies against a wide variety of diseases.
> TheraCour-based drug candidates have demonstrated very high effectiveness in a number of animal models of different diseases.
> TheraCour enables encapsulation of therapeutic cells so that they can be manufactured, protected in the TheraCour gel, and implanted into a patient while minimizing cell death from host effects, to cure degenerative diseases such as Diabetes, Liver Disease, Cardiac Muscle, Neurodegenration, Parkinson's Disease and more."
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
